CA2578748C - Composition and method for prevention or treatment of stomatitis - Google Patents

Composition and method for prevention or treatment of stomatitis Download PDF

Info

Publication number
CA2578748C
CA2578748C CA2578748A CA2578748A CA2578748C CA 2578748 C CA2578748 C CA 2578748C CA 2578748 A CA2578748 A CA 2578748A CA 2578748 A CA2578748 A CA 2578748A CA 2578748 C CA2578748 C CA 2578748C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
glutathione
orotic acid
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2578748A
Other languages
English (en)
French (fr)
Other versions
CA2578748A1 (en
Inventor
Satoru Furukawa
Kenjiro Shimada
Dean Jones
Thomas Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Emory University
Original Assignee
Kyowa Hakko Bio Co Ltd
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd, Emory University filed Critical Kyowa Hakko Bio Co Ltd
Publication of CA2578748A1 publication Critical patent/CA2578748A1/en
Application granted granted Critical
Publication of CA2578748C publication Critical patent/CA2578748C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
CA2578748A 2004-09-03 2005-09-02 Composition and method for prevention or treatment of stomatitis Expired - Lifetime CA2578748C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60705304P 2004-09-03 2004-09-03
US60/607,053 2004-09-03
PCT/US2005/031364 WO2006028991A2 (en) 2004-09-03 2005-09-02 Composition and method for prevention or treatment of stomatits

Publications (2)

Publication Number Publication Date
CA2578748A1 CA2578748A1 (en) 2006-03-16
CA2578748C true CA2578748C (en) 2014-10-14

Family

ID=36036881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2578748A Expired - Lifetime CA2578748C (en) 2004-09-03 2005-09-02 Composition and method for prevention or treatment of stomatitis

Country Status (7)

Country Link
US (1) US8067537B2 (enExample)
EP (1) EP1789068B1 (enExample)
JP (1) JP5066448B2 (enExample)
CN (1) CN101027078B (enExample)
AT (1) ATE516040T1 (enExample)
CA (1) CA2578748C (enExample)
WO (1) WO2006028991A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5408882B2 (ja) * 2008-01-23 2014-02-05 ヤマサ醤油株式会社 唾液分泌促進剤
EP2990048B1 (en) * 2013-01-21 2023-03-01 Kyowa Hakko Bio Co., Ltd. Nitric oxide concentration elevating agent
JP6582983B2 (ja) * 2013-07-31 2019-10-02 味の素株式会社 癌化学療法時の副作用軽減剤
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
EP3485871B1 (en) 2016-07-14 2025-12-24 Resonac Corporation Non-therapeutic use of an orotic acid derivative for inhibiting melanin production and whitening the skin
EP3622957A4 (en) * 2017-05-12 2021-01-27 Furukawa Research Office Co., Ltd. IMPROVING THE DEGREE OF ARTERIAL SATURATION WITH OXYGEN
JP7874258B2 (ja) * 2020-03-31 2026-06-16 株式会社古川リサーチオフィス 亜鉛化合物配合組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2250553A (en) * 1938-04-18 1941-07-29 Simon L Ruskin Medicinal preparation
DE3011437A1 (de) * 1980-03-25 1981-10-01 Hrvoje Dr. Zagreb Krnjevic Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen
US4508898A (en) * 1980-09-16 1985-04-02 Ogilvie Kelvin K Antiviral triazine compounds
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
US5204114A (en) 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
GB9620504D0 (en) * 1996-10-02 1996-11-20 Boehringer Ingelheim Ltd Compositions
WO1998029101A1 (en) 1996-12-31 1998-07-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
EP1402892A4 (en) 2001-06-11 2006-11-08 Kyowa Hakko Kogyo Kk Antiinflammatoric and antitussive compositions
JP2005530738A (ja) * 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び／又は治療のためのクルクミン
JP2003321356A (ja) * 2002-05-01 2003-11-11 Rohto Pharmaceut Co Ltd 催乳作用を有する組成物
US7625928B2 (en) * 2002-10-01 2009-12-01 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
JP4731321B2 (ja) 2003-07-22 2011-07-20 協和発酵バイオ株式会社 ウィルス感染症の予防または治療用組成物

Also Published As

Publication number Publication date
WO2006028991A3 (en) 2006-04-27
HK1099918A1 (en) 2007-08-31
EP1789068A4 (en) 2007-10-17
CN101027078B (zh) 2012-07-04
JP2008512381A (ja) 2008-04-24
US20070259024A1 (en) 2007-11-08
US8067537B2 (en) 2011-11-29
JP5066448B2 (ja) 2012-11-07
EP1789068A2 (en) 2007-05-30
EP1789068B1 (en) 2011-07-13
WO2006028991A2 (en) 2006-03-16
CA2578748A1 (en) 2006-03-16
CN101027078A (zh) 2007-08-29
ATE516040T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
US6582723B2 (en) Cancer immune composition for prevention and treatment of individuals
EP4442241A3 (en) Retinol replacement in skin treatment
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
CA2468916A1 (en) A stable oxaliplatin solution formulation
WO2009076170A3 (en) Combinations of therapeutic agents for treating cancer
MXPA05012901A (es) Composiciones topicas estables, claras, de claritromicina y procesos para su preparacion.
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
CA2374958A1 (en) Compositions normalizing circadian rhythm
UA91332C2 (uk) Кристалічна малеатна сіль хіназоліну (варіанти), корисна як антиангіогенний агент
EP2065040A3 (en) Sphingolipids against pathological processes in lipid rafts
MXPA05012133A (es) Composiciones con un contenido de enzimas, alimentos dieteticos y medicamentos producidos a partir de ellas y su utilizacion para finalidades medicinales.
US20040170701A1 (en) Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection
WO2006042034A3 (en) Salt and crystalline forms thereof of a drug
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
EP1254658A4 (en) MEDICINES
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
US6979468B1 (en) Oral composition and method for the treatment of inflammatory cutaneous disorders
WO2006113495A3 (en) Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
WO2005014032A3 (en) Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
WO2006062424A3 (en) Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
EP2227221B1 (en) Effervescent tablets and effervescent granules containing carnitine tartrate
WO2006022762B1 (en) Compositions and methods for the management of hyperproliferative dermatological conditions
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240829